Significant Ownership of BAKER BROS. ADVISORS LP

Signature - Title
/s/ Scott L. Lessing - Scott L. Lessing/ President
Location
New York, NY
Summary
This page shows a list of all the recent SCHEDULE 13D/G filings made by BAKER BROS. ADVISORS LP.

Notify me when BAKER BROS. ADVISORS LP files a new Schedule 13D/G report.

⭐ Subscribe ⭐

Significant Ownership of BAKER BROS. ADVISORS LP

Sym Company Class Ownership Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
KOD Kodiak Sciences Inc. Common Stock, $0.0001 par value per share 33% $416,802,847 20,067,542 Baker Bros. Advisors LP 18 Dec 2025
ACAD ACADIA Pharmaceuticals Inc. Common Stock, $0.0001 par value per share 25% $1,162,886,859 43,294,373 Julian C. Baker 24 Feb 2026
PRLD Prelude Therapeutics Inc Common Stock, $0.0001 par value per share 24% $8,010,575 10,269,968 Baker Bros. Advisors LP 12 Jun 2025
CELC Celcuity Inc. Common Stock, $0.001 par value per share 19% $103,327,531 +$46,529,346 7,745,692 +82% Baker Bros. Advisors LP 01 Aug 2025
SERA Sera Prognostics, Inc. Class A Common Stock, $0.0001 par value per share 16% $18,418,870 5,498,170 Baker Bros. Advisors LP 12 Feb 2025
INCY Incyte Corp Common Stock, $0.001 par value per share 16% $3,228,403,720 31,213,417 Felix J. Baker 06 Feb 2026
REPL Replimune Group, Inc. Common Stock, $0.001 par value per share 14% $99,960,291 11,045,336 Baker Bros. Advisors LP 07 Mar 2025
KYMR Kymera Therapeutics, Inc. Common Stock, $0.0001 par value per share 11% $551,236,913 +$127,711,627 8,676,797 +30% Baker Bros. Advisors LP 09 Dec 2025
DBVT DBV Technologies S.A. Ordinary shares, nominal value 0.10 euro per share 10% $490,489,821 +$40,190,632 25,586,190 +8.9% Baker Bros. Advisors LP 12 Jan 2026
KALA KALA BIO, Inc. Common Stock, $0.001 par value per share 10% $1,762,934 +$1,308,631 2,890,055 +288% Baker Bros. Advisors LP 31 Dec 2025
IMTX Immatics N.V. Ordinary Shares, nominal value EUR 0.01 per share 10% $103,041,681 +$16,402,644 12,094,094 +19% Baker Bros. Advisors LP 30 Sep 2025
RYTM Rhythm Pharmaceuticals, Inc. Common Stock, par value $0.001 per share 8.9% $360,984,750 5,604,483 Baker Bros. Advisors LP 31 Mar 2025
NRIX Nurix Therapeutics, Inc. Common Stock, par value $0.001 per share 7.2% $138,364,566 7,527,996 Baker Bros. Advisors LP 31 Dec 2025
NGNE Neurogene Inc. Common Stock, par value $0.000001 per share 7% $21,254,360 -$10,597,328 991,804 -33% Julian C. Baker 30 Jun 2025
EWTX Edgewise Therapeutics, Inc. Common Stock, par value $0.0001 per share 6.9% $95,196,398 7,305,940 Baker Bros. Advisors LP 30 Jun 2025
GLUE Monte Rosa Therapeutics, Inc. Common Stock, par value $0.0001 per share 6.7% $104,254,207 4,345,736 Baker Bros. Advisors LP 31 Dec 2025
ALKS Alkermes plc. Ordinary Shares, $0.01 per share 6.1% $280,143,231 10,012,267 Baker Bros. Advisors LP 31 Dec 2025
STOK Stoke Therapeutics, Inc. Common Stock, par value $0.0001 per share 5.8% $105,906,763 3,336,697 Baker Bros. Advisors LP 31 Dec 2025
GRAL GRAIL, Inc. Common Stock, par value $0.001 per share 5.3% $208,741,833 2,085,333 Baker Bros. Advisors LP 31 Dec 2025
CERS Cerus Corporation Common Stock, par value $0.001 per share 5.2% $15,944,852 -$4,572,043 10,028,209 -22% Julian C. Baker 30 Sep 2025
CADL Candel Therapeutics, Inc. Common Stock, par value $0.01 per share 5% $11,882,723 -$2,550,075 2,455,108 -18% Baker Bros. Advisors LP 31 Mar 2025
RVMD Revolution Medicines, Inc. Common Stock, par value $0.0001 per share 4.9% $971,159,717 +$9,283,443 9,455,357 +0.97% Baker Bros. Advisors LP 31 Dec 2025
BMEA Biomea Fusion, Inc. Common Stock, par value $0.0001 per share 4% $3,194,378 1,451,990 Baker Bros. Advisors LP 31 Dec 2024
IGMS IGM Biosciences, Inc. Common Stock, $0.01 par value per share 0% $0 0 Baker Bros. Advisors LP 14 Aug 2025

Schedules 13D/G Reported by BAKER BROS. ADVISORS LP:

Sym Target Class Ownership Change Current Shares Change Value Reporting name Form Report Period Filing Date
* An asterisk sign (*) next to the price indicates that the price is likely invalid.